I currently hold the role of Global Product Leader for several late-stage products in the Haematology Franchise, Oncology Business Unit at AstraZeneca. The role is akin to the CEO of the product, where I lead a cross-functional team accountable for delivering on our ambition for the Haematology Franchise, bringing blood cancer patients closer to uncompromised survival and elevating our leadership position. It’s a real honor to know we are helping patients on a daily basis.

Prior to joining AstraZeneca, I worked at Roche in Switzerland, where I led several strategy programmes in Oncology on the global level, including the creation of a cross-functionally integrated Lung Cancer Franchise across Pharma, Diagnostics and Digital Health. Before moving to Roche, I spent 15 years at AstraZeneca in several development and commercial roles across multiple geographies.

I am personally very passionate about shaping the healthcare environment to make it more sustainable and equitable. I have been elected to several industry boards and private biotech companies and hold several honourary positions outside of AstraZeneca.

I have received my MBA, PhD, MSc and Lean Sigma Master Black Belt and am a co-author of the industry renowned 5Rs publication.


For those who have been touched by the diseases we work on, it’s a real honour to be CEO of some of the most critical products in our pipeline, where we are making a meaningful difference for patients. It’s a pleasure to have the opportunity to work with dedicated and passionate people every day and push the boundaries of science together so we can all be part of AstraZeneca’s legacy of using innovative science to transform healthcare for the better.

Gemma Satterthwaite Global Product Leader, Oncology Business Unit, AstraZeneca

Headshot of Gemma Satterthwaite, Global Product Leader, Oncology Business Unit at AstraZeneca

CURRENT ROLE

Global Product Leader, Oncology Business Unit, AstraZeneca

2022 - present: Global Product Leader, Oncology Business Unit, AstraZeneca

CEO of haematology product launched in >80 countries worldwide (2022)

2022

Elected to the board of the Medical Research Council

2020: Executive Project Team Leader, Oncology, Roche

CEO of the first Immuno-Oncology product to secure approval of subcutaneous formulation in several indications to enable increased convenience for patients

2020: Integrated Strategy Leader, Lung Cancer and Rare Disease Franchise, Roche

Creation of a cross-functionally integrated Lung Franchise across Pharma, Diagnostic and Digital Health

2019

Elected to EFPIA (European Federation of Pharmaceutical Industries and Associations) Board for Health and Science Policy

Veeva ID: Z4-50602 
Date of preparation: November 2022